Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

• Published in: The New England journal of medicine Vol. 385; no. 20; pp. 1856 - 1867
• Main Authors: Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M. Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu S, Salman, Pamela, Hoyos Usta, Edwin, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen M, Monk, Bradley J
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 11.11.2021
• Subjects: Adult; Adverse events; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Apoptosis; Bevacizumab; Cancer therapies; Carcinoma - drug therapy; Carcinoma - mortality; Carcinoma - secondary; Cervical cancer; Cervix; Chemotherapy; Death; Double-Blind Method; Female; Gynecologic Oncology; Gynecology; Hematology; Humans; Hypotheses; Immunotherapy; Intention to Treat Analysis; Laboratories; Metastases; Metastasis; Middle Aged; Monoclonal antibodies; Neoplasm Staging; Neutropenia; Obstetrics; Oncology; Patient Reported Outcome Measures; Patients; PD-L1 protein; Pembrolizumab; Placebos; Progression-Free Survival; Radiation therapy; Statistical analysis; Survival Analysis; Targeted cancer therapy; Treatments in Oncology; Tumor cells; Tumors; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - mortality; Uterine Cervical Neoplasms - pathology
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa2112435

A randomized, double-blind trial compared pembrolizumab with placebo in patients with advanced cervical cancer who were also receiving platinum-based chemotherapy with or without bevacizumab. The median progression-free survival was 10.4 months with pembrolizumab and 8.2 months with placebo. Overall survival at 2 years was 50.4% and 40.4%, respectively.